Aveo Pharmaceuticals, Inc.

Osi Pharmaceuticals, Inc.

Joerg Heyer

Steven C Clark

Tyler E Jacks

Maria Isabel Chiu

Murray O Robinson

Murray Robinson

Bin Feng

Ronan O'Hagan

Julie Kan

Stuart Thomson

Yinghui Zhou

Richard Nicoletti

Matthew O'Connor

Ronald A Depinho

Ronald Depinho

William Rideout, Iii

Gretchen M Argast

William Iii Rideout

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.

Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment

Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.

Chimeric cancer models

Growing community of inventors

Newton, MA, United States of America

Joerg Heyer